HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation
Table 3
Demographics of patients delisted in 2014-2015.
HCV (N=43)
Non-HCV (N=54)
P Value (subgroups)
Age, mean±SD, [range]
55.9±5.3
45.5±20.2
Gender, N=Male ( Male)
30 (69.8)
27 (50.0)
MELD-Na at listing, mean±SD [range]
14.1±1.2
16.9±1.1
Blood group, N ()
A
19 (44.2)
16 (29.6)
AB
2 (4.7)
1 (1.8)
B
5 (11.6)
8 (14.8)
O
17 (39.5)
29 (53.7)
HCV Genotype, N ()
1
27 (62.8)
N/A
2
4 (9.3)
3
11 (25.6)
4
1 (2.3)
Reason for Delisting, N ()
Noncompliance
9 (20.9)
10 (18.5)
Death on waiting list
11 (25.6)
15 (27.7)
Clinical deterioration/ medical contraindication
7(16.2)
15 (27.7)
HCC tumor progression
13 (30.2)
3 (5.6)
Clinical improvement
1 (2.3)
5 (9.3)
Moved/transplanted elsewhere/other
2 (4.6)
6 (11.1)
Patients also with HCC, N ()
22 (51.1)
7 (12.9%)
Listing AFP, mean±SD, [range]
23.5±28.9
10.1±7.1
Listing TTV, mean±SD, [range]
9.0±12.3
4.2±5.2
Listing # tumors, mean±SD, [range]
1.6±1.9
1.4±1.1
Within Milan Criteria at Listing, N ()
12/16 (75%)
5/5 (100%)
Days between last HCC treatment and delisting, mean±SD, [range]
181.1±139.5
355.0±522.6
HCV patients with HCC, N ()
Untreated HCV ( patients HCV/HCC)
16 (72.7)
Patients with SVR ( patients with HCV/HCC)
6 (27.3)
HCV SVR, N ( of subgroup)
HCV alone, Total N=21
4 (19.0)
0.523
HCV/HCC, Total N=22
6 (27.3)
HCC progression, N ( of subgroup)
Untreated HCV, Total N=16
11 (68.8)
0.415
Patients with SVR, Total N=6
3 (50.0)
Death after delisting, N ( of subgroup)
Untreated HCV, Total N=26
23 (88.5)
0.022
Patients with SVR, Total N=13
5 (45.5)
Data for this subgroup includes N=16 HCV/HCC patients and N= HCC (non-HCV) patients, as not all patients who were delisted have detailed HCC data in our registry. Two patients in the HCC (non-HCV) analysis did not receive HCC treatment between listing and delisting.
